Tilray Brands, Inc. (NASDAQ:TLRY) Receives Average Rating of “Hold” from Analysts

Tilray Brands, Inc. (NASDAQ:TLRY) has been given an average rating of “Hold” by the eight analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $13.3333.

TLRY has been the subject of a number of recent analyst reports. ATB Cormark Capital Markets upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 10th. Roth Mkm dropped their target price on shares of Tilray Brands from $20.00 to $10.00 and set a “neutral” rating for the company in a report on Tuesday, January 20th. Zacks Research upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday. Canaccord Genuity Group initiated coverage on shares of Tilray Brands in a research report on Tuesday, January 27th. They set a “hold” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tilray Brands in a research note on Wednesday, January 21st.

Tilray Brands Stock Performance

Tilray Brands stock opened at $7.51 on Friday. The firm has a 50 day simple moving average of $9.13 and a 200-day simple moving average of $10.99. The stock has a market cap of $874.99 million, a price-to-earnings ratio of -0.34 and a beta of 2.02. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.81 and a quick ratio of 1.72. Tilray Brands has a 1-year low of $3.51 and a 1-year high of $23.20.

Tilray Brands (NASDAQ:TLRY) last issued its quarterly earnings data on Thursday, January 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.27). The business had revenue of $217.51 million for the quarter, compared to analyst estimates of $211.15 million. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.During the same period in the previous year, the business posted ($0.03) earnings per share. On average, analysts expect that Tilray Brands will post -0.2 EPS for the current year.

Institutional Investors Weigh In On Tilray Brands

A number of hedge funds have recently bought and sold shares of the stock. Hilton Head Capital Partners LLC purchased a new position in Tilray Brands in the fourth quarter valued at about $38,000. IFP Advisors Inc grew its holdings in shares of Tilray Brands by 14.3% in the 4th quarter. IFP Advisors Inc now owns 60,318 shares of the company’s stock worth $545,000 after acquiring an additional 7,541 shares during the period. Integrated Wealth Concepts LLC increased its stake in Tilray Brands by 33.8% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 36,977 shares of the company’s stock valued at $64,000 after purchasing an additional 9,341 shares in the last quarter. CreativeOne Wealth LLC raised its holdings in Tilray Brands by 12.2% during the third quarter. CreativeOne Wealth LLC now owns 87,134 shares of the company’s stock worth $151,000 after purchasing an additional 9,452 shares during the last quarter. Finally, Dudley Capital Management LLC raised its holdings in Tilray Brands by 73.3% during the third quarter. Dudley Capital Management LLC now owns 26,000 shares of the company’s stock worth $45,000 after purchasing an additional 11,000 shares during the last quarter. Institutional investors and hedge funds own 9.35% of the company’s stock.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.